Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial

NCT06313567 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06313567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06313567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
March 10, 2024
Completion date
March 10, 2029
Enrollment
722 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer